1. Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe
- Author
-
Fruzsina Kósa, Tereza Nečasová, Martin Špaček, Krzysztof Giannopoulos, Iwona Hus, Tereza Jurková, Eva Koriťáková, Marika Chrápavá, Martina Nováčková, Ivana Katinová, Denisa Krejčí, Adam Jujka, Zoltán Mátrai, István Vályi‐Nagy, Tadeusz Robak, and Michael Doubek
- Subjects
CLL population ,FCR therapy ,secondary malignancy ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract This is the first large‐scale cross‐country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first‐line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p
- Published
- 2023
- Full Text
- View/download PDF